Miwa Kishimoto1,2, Hayato Yamana3, Satoki Inoue4, Tatsuya Noda5, Tomoya Myojin5, Hiroki Matsui3, Hideo Yasunaga3, Masahiko Kawaguchi4, Tomoaki Imamura5. 1. Department of Public Health, Health Management and Policy, Nara Medical University, 840 Shijo-cho, Kashihara, Nara, 634-0813, Japan. miwakishimoto@gmail.com. 2. Department of Anesthesiology, Nara Medical University, 840 Shijo-cho, Kashihara, Nara, 634-0813, Japan. miwakishimoto@gmail.com. 3. Department of Clinical Epidemiology and Health Economics, School of Public Health, Graduate School of Medicine, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-0033, Japan. 4. Department of Anesthesiology, Nara Medical University, 840 Shijo-cho, Kashihara, Nara, 634-0813, Japan. 5. Department of Public Health, Health Management and Policy, Nara Medical University, 840 Shijo-cho, Kashihara, Nara, 634-0813, Japan.
Abstract
PURPOSE: Sivelestat is widely used in Japan for the treatment of acute respiratory distress syndrome caused by pneumonia. Although the efficacy of sivelestat was reported in several Japanese studies in the early 2000 s, a multinational randomized control trial did not support these findings. We therefore conducted the present study to examine the association between the use of sivelestat and mortality in pneumonia patients requiring mechanical ventilation. METHODS: We conducted a retrospective observational study using the Diagnosis Procedure Combination database, a national inpatient database in Japan. We identified pneumonia patients requiring mechanical ventilation who were hospitalized between April 2012 and March 2014. Propensity score matching was performed to compare 7- and 30-day mortality between patients with and without sivelestat use. RESULTS: The eligible patients (n = 16,471) were categorized into the sivelestat (n = 1707) and control (n = 14,764) groups. The unmatched comparison showed significant differences between the sivelestat and control groups in both 7-day mortality (11.0 vs. 7.6%, p < 0.001) and 30-day mortality (29.9 vs. 19.7%, p < 0.001). In the 1516 pairs of propensity-matched patients, there were no significant differences in 7-day mortality (sivelestat vs. CONTROL: 10.2 vs. 10.9%, p = 0.516) and 30-day mortality (sivelestat vs. control 29.0 vs. 29.0%, p = 1.000). CONCLUSIONS: The propensity-matched analyses revealed that the use of sivelestat was not associated with decreased mortality for pneumonia patients requiring mechanical ventilation.
PURPOSE:Sivelestat is widely used in Japan for the treatment of acute respiratory distress syndrome caused by pneumonia. Although the efficacy of sivelestat was reported in several Japanese studies in the early 2000 s, a multinational randomized control trial did not support these findings. We therefore conducted the present study to examine the association between the use of sivelestat and mortality in pneumoniapatients requiring mechanical ventilation. METHODS: We conducted a retrospective observational study using the Diagnosis Procedure Combination database, a national inpatient database in Japan. We identified pneumoniapatients requiring mechanical ventilation who were hospitalized between April 2012 and March 2014. Propensity score matching was performed to compare 7- and 30-day mortality between patients with and without sivelestat use. RESULTS: The eligible patients (n = 16,471) were categorized into the sivelestat (n = 1707) and control (n = 14,764) groups. The unmatched comparison showed significant differences between the sivelestat and control groups in both 7-day mortality (11.0 vs. 7.6%, p < 0.001) and 30-day mortality (29.9 vs. 19.7%, p < 0.001). In the 1516 pairs of propensity-matched patients, there were no significant differences in 7-day mortality (sivelestat vs. CONTROL: 10.2 vs. 10.9%, p = 0.516) and 30-day mortality (sivelestat vs. control 29.0 vs. 29.0%, p = 1.000). CONCLUSIONS: The propensity-matched analyses revealed that the use of sivelestat was not associated with decreased mortality for pneumoniapatients requiring mechanical ventilation.
Authors: G R Bernard; A Artigas; K L Brigham; J Carlet; K Falke; L Hudson; M Lamy; J R Legall; A Morris; R Spragg Journal: Am J Respir Crit Care Med Date: 1994-03 Impact factor: 21.405
Authors: Gordon D Rubenfeld; Ellen Caldwell; Eve Peabody; Jim Weaver; Diane P Martin; Margaret Neff; Eric J Stern; Leonard D Hudson Journal: N Engl J Med Date: 2005-10-20 Impact factor: 91.245
Authors: Bernhardt G Zeiher; Antonio Artigas; Jean-Louis Vincent; Alexei Dmitrienko; Kimberley Jackson; B Taylor Thompson; Gordon Bernard Journal: Crit Care Med Date: 2004-08 Impact factor: 7.598
Authors: M Monchi; F Bellenfant; A Cariou; L M Joly; D Thebert; I Laurent; J F Dhainaut; F Brunet Journal: Am J Respir Crit Care Med Date: 1998-10 Impact factor: 21.405